Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Therapy Combining Raltegravir With Etravirine in HIV-infected Individuals Over 45 Years
NCT02212379Phase 2Completed
- Sponsor
- ANRS
- Start
- Jan 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of raltegravir and etravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ANRS. Primary endpoint: Percentage of Participants With Successful Virological Suppression at 96 weeks. Started Jan 2015; status: completed.
02
Drugs
raltegraviretravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02212379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212379.